Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 3 Genitourinary 2 Gastrointestinal 2 Dermatologic 2 Sarcoma 1 Other 1 Lymphoid 1 Head & Neck 1 CNS 1 Breast 1

Conditions

Sarcoma 1 Liposarcoma 1

Interventions

Radiotherapy 137 Cyclophosphamide 132 Temozolomide 116 Doxorubicin 99 Filgrastim 68 Ifosfamide 64 Gemcitabine 58 Etoposide 55 Bevacizumab 51 Imatinib Mesylate 50 fludarabine phosphate 49 Irinotecan 46 pembrolizumab 45 Peripheral Blood Stem Cell Transplantation 45 pazopanib 43 Magnetic Resonance Spectroscopy 42 Methotrexate 40 Carboplatin 40 Busulfan 40 Vincristine 38 Surgical Procedures, Operative 37 Nivolumab 37 Melphalan 37 Cisplatin 36 Radiation 34 Blood Specimen Collection 33 Mycophenolic Acid 31 Cyclosporine 31 Docetaxel 29 Trabectedin 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rosiglitazone × Sarcoma × Clear all

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡